Key result
A review of 10 antiplatelet stroke prevention trials (N=40,730) found total subject discontinuation ranged from 11.8-52.0%, with up to a 20% discrepancy compared to specific reported reasons.
Why the study?
What are the rates of attrition and non-compliance in secondary stroke prevention trials?
Population
40,730 subjects from 10 antiplatelet secondary stroke prevention clinical trials
Design
Review
Authors
Loading...
May underestimate adverse events via reporting gaps; leaves open standardization of discontinuation metrics in prevention trials.
What are the rates of attrition and non-compliance in secondary stroke prevention trials?
There is a substantial discrepancy between total subject discontinuation and reported specific reasons in stroke prevention trials, which may lead to underestimation of adverse events and limit clinical translation.
Gencheva et al. (2004) conducted a review in Secondary stroke prevention (n=40,730). Antiplatelet therapy was evaluated on Frequencies for total subject discontinuation, voluntary withdrawal, and loss to follow-up. A review of 10 antiplatelet stroke prevention trials (N=40,730) found total subject discontinuation ranged from 11.8-52.0%, with up to a 20% discrepancy compared to specific reported reasons.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: